Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer
- Resource Type
- Article
- Authors
- Cope, Shannon; Keeping, Sam T; Goldgrub, Rachel; Ayers, Dieter; Jansen, Jeroen P; Penrod, John R; Korytowsky, Beata; Juarez-Garcia, Ariadna; Yuan, Yong
- Source
- Journal of Comparative Effectiveness Research; July 2019, Vol. 8 Issue: 10 p733-751, 19p
- Subject
- Language
- ISSN
- 20426305; 20426313
Aim:To estimate the comparative efficacy of nivolumab ± ipilimumab versus alternative treatments for small-cell lung cancer after at least one prior line of chemotherapy. Materials & methods:A systematic literature review identified six randomized controlled trials (RCTs) that could be connected in a network. The Kaplan–Meier survival curves from these RCTs were synthesized using network meta-analysis models. Aggregate-level matching was used to connect CheckMate 032 to the RCTs. Results:CheckMate 032 was connected to the network by Amrubicin Clinical Trial-1. Nivolumab ± ipilimumab had a more durable tumor response and more favorable long-term survival versus topotecan via intravenous and versus amrubicin. Conclusion:Compared with chemotherapies for recurrent small-cell lung cancer, nivolumab ± ipilimumab improves response duration, which may translate to long-term survival benefits.